Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 28, 2007

Salix Purchases Pepcid and Diuril from Merck & Co. for $55M

  • Salix Pharmaceuticals purchased the U.S. prescription pharmaceutical product rights to Pepcid® Oral Suspension and Diuril® Oral Suspension from Merck & Co. 

    Pepcid Oral Suspension is indicated for several gastrointestinal indications, including the treatment of duodenal ulcer, benign gastric ulcer, and gastroesophageal reflux disease. Diuril Oral Suspension has applications in edema and hypertension.

    Under the terms of the agreement, Salix will make a $55 million up-front payment and up to $6 million in potential sales-based milestone payments to Merck.

    Commenting on this development, Carolyn Logan, president and CEO, Salix, stated, "These marketed products should generate immediate revenue while requiring minimal promotional expense. Pepcid Oral Suspension achieved net sales in the U.S. of approximately $20 million in 2006.”



Be sure to take the GEN Poll

Cancer vs. Zika: What Worries You Most?

While Zika continues to garner a lot of news coverage, a Mayo Clinic survey reveals that Americans believe the country’s most significant healthcare challenge is cancer. Compared to other diseases, does the possibility of developing cancer worry you the most?

More »